Genome editing
≈ 10 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
s used for genome editing and the DNA repair pathways used to modify target DNA. Genome editing, or genome engineering, or gene editing, is a type of genetic engineering in which DNA is inserted, deleted, modified or replaced in the genome of a living organism. Unlike early genetic engineering techniques that randomly insert genetic material into a host genome, genome editing targets the insertions to site-specific locations.
Programmable molecules called restriction endonucleases, also known as gene editors or molecular scissors, are used to create double-strand breaks (DSBs) at desired locations in the genome. The induced breaks are repaired through homology-directed recombination (HDR) or non-homologous end joining (NHEJ), resulting in targeted mutations. The development of CRISPR gene editing in 2015 improved the efficiency, specificity, and practicality of large-scale genome editing. One of the earliest and most efficient methods of geonome editing is base editing.
It does not require breaking and recombining the genomic DNA strands, and thus avoids the random insertions and deletions associated with these procedures. However, it is only appropriate for precise editing of single nucleotides. It employs nucleobase modifying enzymes directed by nucleic acid guide sequences. It was first described in the 1990s and has seen a resurgence more recently.…
s used for genome editing and the DNA repair pathways used to modify target DNA. Genome editing, or genome engineering, or gene editing, is a type of genetic engineering in which DNA is inserted, deleted, modified or replaced in the genome of a living organism. Unlike early genetic engineering techniques that randomly insert genetic material into a host genome, genome editing targets the insertions to site-specific locations.
Programmable molecules called restriction endonucleases, also known as gene editors or molecular scissors, are used to create double-strand breaks (DSBs) at desired locations in the genome. The induced breaks are repaired through homology-directed recombination (HDR) or non-homologous end joining (NHEJ), resulting in targeted mutations. The development of CRISPR gene editing in 2015 improved the efficiency, specificity, and practicality of large-scale genome editing. One of the earliest and most efficient methods of geonome editing is base editing.
It does not require breaking and recombining the genomic DNA strands, and thus avoids the random insertions and deletions associated with these procedures. However, it is only appropriate for precise editing of single nucleotides. It employs nucleobase modifying enzymes directed by nucleic acid guide sequences. It was first described in the 1990s and has seen a resurgence more recently. Since 2015, genome editing has been experimentally investigated on non-viable human embryos.
In 2019, the first humans were born from genome-edited embryos using the CRISPR technique, as a result of the controversial He Jiankui affair.
History
Genome editing was pioneered in the 1990s, before the advent of the common current nuclease-based gene-editing platforms, but its use was limited by low efficiencies of editing. In the 2000s, genome editing with engineered nucleases (also known as "molecular scissors") was introduced. , three families of engineered nucleases were used: meganucleases, zinc finger nucleases (ZFNs), transcription activator-like effector-based nucleases (TALEN). All of them were selected by Nature Methods as the 2011 Method of the Year.
In 2015 the CRISPR-Cas system was introduced, and it was selected by Science as 2015 Breakthrough of the Year. Nine genome editors were available . In 2018, the common methods for such editing used engineered nucleases to create double-strand breaks (DSBs) at desired locations in the genome. The induced double-strand breaks are repaired through nonhomologous end-joining (NHEJ) or homologous recombination (HR), resulting in targeted mutations ('edits').
In May 2019, lawyers in China reported, in light of the purported creation by Chinese scientist He Jiankui of the first gene-edited humans (see Lulu and Nana controversy), the drafting of regulations that anyone manipulating the human genome by gene-editing techniques, like CRISPR, would be held responsible for any related adverse consequences. A cautionary perspective on the possible blind spots and risks of CRISPR and related biotechnologies has been recently discussed, focusing on the stochastic nature of cellular control processes.
The University of Edinburgh Roslin Institute engineered pigs resistant to a virus that causes porcine reproductive and respiratory syndrome, which costs US and European pig farmers $2.6 billion annually. In February 2020, a US trial safely showed CRISPR gene editing on 3 cancer patients. In 2020 Sicilian Rouge High GABA, a tomato that makes more of an amino acid said to promote relaxation, was approved for sale in Japan.
In 2021, England (not the rest of the UK) planned to remove restrictions on gene-edited plants and animals, moving from European Union-compliant regulation to rules closer to those of the US and some other countries. An April 2021 European Commission report found "strong indications" that the current regulatory regime was not appropriate for gene editing.
Later in 2021, researchers announced a CRISPR alternative, labelled obligate mobile element–guided activity (OMEGA) proteins including IscB, IsrB and TnpB as endonucleases found in transposons, and guided by small ωRNAs. In 2026, Zilong Qiu and his team at the Shanghai Jiao Tong University School of Medicine, published successful use of base editing in mice and monkeys to induce corrected CHD3 gene that causes Snijders Blok–Campeau syndrome.
It was subsequently discovered that a year before, Qiu had treated a six-year-old girl at Xinhua Hospital in Shanghai using engineered viruses to carry the corrected gene into the spinal fluid. The girl died of thrombotic microangiopathy several days later.
Meganucleases
Meganucleases, discovered in the late 1980s, are enzymes in the endonuclease family which are characterized by their capacity to recognize and cut large DNA sequences (from 14 to 40 base pairs). The most widespread and best known meganucleases are the proteins in the LAGLIDADG family, which owe their name to a conserved amino acid sequence. Meganucleases, found commonly in microbial species, have the unique property of having very long recognition sequences (>14bp) thus making them naturally very specific.
However, there is virtually no chance of finding the exact meganuclease required to act on a chosen specific DNA sequence. To overcome this challenge, mutagenesis and high throughput screening methods have been used to create meganuclease variants that recognize unique sequences. Others have been able to fuse various meganucleases and create hybrid enzymes that recognize a new sequence.
Yet others have attempted to alter the DNA interacting aminoacids of the meganuclease to design sequence specific meganucleases in a method named rationally designed meganuclease. Another approach involves using computer models to try to predict as accurately as possible the activity of the modified meganucleases and the specificity of the recognized nucleic sequence. A large bank containing several tens of thousands of protein units has been created.
These units can be combined to obtain chimeric meganucleases that recognize the target site, thereby providing research and development tools that meet a wide range of needs (fundamental research, health, agriculture, industry, energy, etc.) These include the industrial-scale production of two meganucleases able to cleave the human XPC gene; mutations in this gene result in Xeroderma pigmentosum, a severe monogenic disorder that predisposes the patients to skin cancer and burns whenever their skin is exposed to UV rays.
Meganucleases have the benefit of causing less toxicity in cells than methods such as Zinc finger nuclease (ZFN), likely because of more stringent DNA sequence recognition; however, the construction of sequence-specific enzymes for all possible sequences is costly and time-consuming, as one is not benefiting from combinatorial possibilities that methods such as ZFNs and TALEN-based fusions utilize.
TALEN
Transcription activator-like effector nucleases (TALENs) are specific DNA-binding proteins that feature an array of 33 or 34-amino acid repeats. TALENs are artificial restriction enzymes designed by fusing the DNA cutting domain of a nuclease to TALE domains, which can be tailored to specifically recognize a unique DNA sequence. These fusion proteins serve as readily targetable "DNA scissors" for gene editing applications that enable to perform targeted genome modifications such as sequence insertion, deletion, repair and replacement in living cells.
The DNA binding domains, which can be designed to bind any desired DNA sequence, comes from TAL effectors, DNA-binding proteins excreted by plant pathogenic Xanthomanos app. TAL effectors consists of repeated domains, each of which contains a highly conserved sequence of 34 amino acids, and recognize a single DNA nucleotide within the target site.
The nuclease can create double strand breaks at the target site that can be repaired by error-prone non-homologous end-joining (NHEJ), resulting in gene disruptions through the introduction of small insertions or deletions. Each repeat is conserved, with the exception of the so-called repeat variable di-residues (RVDs) at amino acid positions 12 and 13. The RVDs determine the DNA sequence to which the TALE will bind.
This simple one-to-one correspondence between the TALE repeats and the corresponding DNA sequence makes the process of assembling repeat arrays to recognize novel DNA sequences straightforward. These TALEs can be fused to the catalytic domain from a DNA nuclease, FokI, to generate a transcription activator-like effector nuclease (TALEN). The resultant TALEN constructs combine specificity and activity, effectively generating engineered sequence-specific nucleases that bind and cleave DNA sequences only at pre-selected sites.
The TALEN target recognition system is based on an easy-to-predict code. TAL nucleases are specific to their target due in part to the length of their 30+ base pairs binding site. TALEN can be performed within a 6 base pairs range of any single nucleotide in the entire genome. TALEN constructs are used in a similar way to designed zinc finger nucleases, and have three advantages in targeted mutagenesis: (1) DNA binding specificity is higher, (2) off-target effects are lower, and (3) construction of DNA-binding domains is easier.
CRISPR
CRISPRs (Clustered Regularly Interspaced Short Palindromic Repeats) are genetic elements that bacteria use as a kind of acquired immunity to protect against viruses. They consist of short sequences that originate from viral genomes and have been incorporated into the bacterial genome. Cas (CRISPR associated proteins) process these sequences and cut matching viral DNA sequences. By introducing plasmids containing Cas genes and specifically constructed CRISPRs into eukaryotic cells, the eukaryotic genome can be cut at any desired position.
Research
Text derived from https://en.wikipedia.org/w/index.php?oldid=1378460428 under CC BY-SA 4.0; modifications have been made.